OncoTherapy Science (FRA:30O) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30O OncoTherapy Science Inc FRA:30O
50 GF Score
Price €0.08
GF Value €0.08
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

OncoTherapy Science's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:30O vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, OncoTherapy Science's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoTherapy Science Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Margin of Safety % (DCF Earnings Based) falls into.


FRA:30O
50GF Score
OncoTherapy Science Inc FRA:30O
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OncoTherapy Science (FRA:30O) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of €0.08 is trading 3.1% above its estimated GF Value™ of €0.08. GuruFocus considers OncoTherapy Science to be Fairly Valued.

Key valuation signals for FRA:30O:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.08 vs. price of €0.08 (3.1% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 4564:Japan
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for FRA:30O

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.08
GF Value